BMS Projects 2022 Growth Even With $3bn Hit From Revlimid, Abraxane Generics

Current Blockbusters, New Products To Make Up Difference

 
• By Mandy Jackson
  
Financial Stock Market Graphs Candle Chart ROI Return On Investment Business Concept
BMS guided low single-digit revenue growth for 2022 but has loftier projections in the years beyond • Source: Alamy
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from New Products

More from Scrip